Ikaria completes patient enrollment for phase III trial for bronchopulmonary dysplasia
Ikaria Inc, Hampton, NJ, has completed patient enrollment for its phase III trial investigating the use of inhaled nitric oxide in premature infants with bronchopulmonary dysplasia.
Before you can understand how to treat bronchitis, you have to know what bronchitis is.